SABER-Bupivacaine Reduces Postoperative Pain and Opioid Consumption After Arthroscopic Subacromial Decompression: A Randomized, Placebo-Controlled Trial.
Anders EkelundAndrejs PeredistijsJosef Georg GrohsJon MeisnerNeil VeritySten RasmussenPublished in: Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews (2022)
Compared with placebo, SABER-Bupivacaine reduced pain and opioid analgesic consumption over 72 hours after arthroscopic subacromial decompression and prolonged the time to first use of opioid rescue analgesia. No safety signals were noted during the immediate postoperative period or at 6-month follow-up.